These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 27603288)
1. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. Kelesidis T; Jackson N; McComsey GA; Wang X; Elashoff D; Dube MP; Brown TT; Yang OO; Stein JH; Currier JS AIDS; 2016 Nov; 30(17):2625-2633. PubMed ID: 27603288 [TBL] [Abstract][Full Text] [Related]
2. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466 [TBL] [Abstract][Full Text] [Related]
3. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376 [TBL] [Abstract][Full Text] [Related]
4. Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217. Macatangay BJ; Yang M; Sun X; Morton J; De Gruttola V; Little S; Hogan C; Rinaldo CR; J Acquir Immune Defic Syndr; 2017 May; 75(1):137-141. PubMed ID: 28198712 [TBL] [Abstract][Full Text] [Related]
5. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. Wilson EM; Singh A; Hullsiek KH; Gibson D; Henry WK; Lichtenstein K; Önen NF; Kojic E; Patel P; Brooks JT; Sereti I; Baker JV; J Infect Dis; 2014 Nov; 210(9):1396-406. PubMed ID: 24813472 [TBL] [Abstract][Full Text] [Related]
6. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. Kousari A; Moser C; Olefsky M; Brown TT; Currier JS; McComsey GA; Scherzinger A; Stein JH; Lake JE; Erlandson KM J Acquir Immune Defic Syndr; 2021 Dec; 88(4):399-405. PubMed ID: 34326283 [TBL] [Abstract][Full Text] [Related]
7. Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adults. Zhang Z; Chew GM; Shikuma CM; Gangcuangco LMA; Souza SA; Shiramizu B; Nakamoto BK; Gong T; Mannem SR; Mitchell BI; Kallianpur KJ; Ndhlovu LC; Chow DC HIV Clin Trials; 2018 Oct; 19(5):172-176. PubMed ID: 30422099 [TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. Funderburg NT; Jiang Y; Debanne SM; Labbato D; Juchnowski S; Ferrari B; Clagett B; Robinson J; Lederman MM; McComsey GA J Acquir Immune Defic Syndr; 2015 Apr; 68(4):396-404. PubMed ID: 25514794 [TBL] [Abstract][Full Text] [Related]
9. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers. Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R AIDS; 2017 Jul; 31(11):1529-1534. PubMed ID: 28463882 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal evaluation of markers of inflammation in HIV-positive and HIV-negative Rwandan women. Kiefer EM; Hoover DR; Shi Q; Dusingize JC; Sinayobye JD; Anastos K HIV Med; 2018 Nov; 19(10):734-744. PubMed ID: 30160347 [TBL] [Abstract][Full Text] [Related]
11. Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. Castillo-Mancilla JR; Morrow M; Boum Y; Byakwaga H; Haberer JE; Martin JN; Bangsberg D; Mawhinney S; Musinguzi N; Huang Y; Tracy RP; Burdo TH; Williams K; Muzzora C; Hunt PW; Siedner MJ J Acquir Immune Defic Syndr; 2018 Apr; 77(5):507-513. PubMed ID: 29346185 [TBL] [Abstract][Full Text] [Related]
12. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. Hileman CO; Kinley B; Scharen-Guivel V; Melbourne K; Szwarcberg J; Robinson J; Lederman MM; Mccomsey GA J Infect Dis; 2015 Aug; 212(3):345-54. PubMed ID: 25583168 [TBL] [Abstract][Full Text] [Related]
13. Cigarette Smoking and Inflammation, Monocyte Activation, and Coagulation in HIV-Infected Individuals Receiving Antiretroviral Therapy, Compared With Uninfected Individuals. Kooij KW; Wit FW; Booiman T; van der Valk M; Schim van der Loeff MF; Kootstra NA; Reiss P; J Infect Dis; 2016 Dec; 214(12):1817-1821. PubMed ID: 27683822 [TBL] [Abstract][Full Text] [Related]
14. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. Conley LJ; Bush TJ; Rupert AW; Sereti I; Patel P; Brooks JT; Baker JV; AIDS; 2015 Oct; 29(16):2201-7. PubMed ID: 26544583 [TBL] [Abstract][Full Text] [Related]
15. Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART. Chiappetta S; Ripa M; Galli L; Razzari C; Longo V; Galli A; Faioni EM; Nozza S; Lazzarin A; Tambussi G J Antimicrob Chemother; 2016 Jun; 71(6):1627-31. PubMed ID: 26888911 [TBL] [Abstract][Full Text] [Related]
16. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. Erlandson KM; OʼRiordan M; Labbato D; McComsey GA J Acquir Immune Defic Syndr; 2014 Mar; 65(3):290-8. PubMed ID: 24525466 [TBL] [Abstract][Full Text] [Related]
17. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. Baker JV; Neuhaus J; Duprez D; Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon DE; Paton NI; Neaton JD; J Acquir Immune Defic Syndr; 2011 Jan; 56(1):36-43. PubMed ID: 20930640 [TBL] [Abstract][Full Text] [Related]
18. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Kelesidis T; Moser C; Stein JH; Brown TT; Tran TT; Ribaudo HJ; Dube MP; Yang OO; Currier JS; McComsey GA J Infect Dis; 2016 Sep; 214(5):748-52. PubMed ID: 27354367 [TBL] [Abstract][Full Text] [Related]
19. Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. Di Yacovo S; Saumoy M; Sánchez-Quesada JL; Navarro A; Sviridov D; Javaloyas M; Vila R; Vernet A; Low H; Peñafiel J; García B; Ordoñez-Llanos J; Podzamczer D PLoS One; 2020; 15(8):e0237739. PubMed ID: 32817629 [TBL] [Abstract][Full Text] [Related]
20. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]